These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 6216501)

  • 1. Central nervous system receptors in neuropsychiatric disorders.
    Kato G; Ban T
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(3):207-22. PubMed ID: 6216501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of non-opioid peptides in the pathogenesis of neurological and psychiatric disorders: evidence from CSF and post-mortem studies.
    Nemeroff CB; Bissette G
    Prog Clin Biol Res; 1985; 192():333-41. PubMed ID: 2934745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotransmitter receptors-biochemistry and alterations in nueropsychiatric disorders.
    Olsen RW; Reisine TD; Yamamura HI
    Life Sci; 1980 Sep; 27(10):801-8. PubMed ID: 6251327
    [No Abstract]   [Full Text] [Related]  

  • 4. Postmortem and cerebrospinal fluid studies of corticotropin-releasing factor in humans.
    Hartline KM; Owens MJ; Nemeroff CB
    Ann N Y Acad Sci; 1996 Mar; 780():96-105. PubMed ID: 8602742
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurochemical and neuropharmacological indications for the involvement of GABA and glycine receptors in neuropsychiatric disorders.
    Lloyd KG; DeMontis G; Broekkamp CL; Thuret F; Worms P
    Adv Biochem Psychopharmacol; 1983; 37():137-48. PubMed ID: 6138947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropsychiatric disorders and the multiple human brain serotonin receptor subtypes and subsystems.
    Murphy DL
    Neuropsychopharmacology; 1990; 3(5-6):457-71. PubMed ID: 2078279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of metabotropic glutamate receptors into active neurodegenerative processes: A "dark side" in the development of new symptomatic treatments for neurologic and psychiatric disorders.
    Bruno V; Caraci F; Copani A; Matrisciano F; Nicoletti F; Battaglia G
    Neuropharmacology; 2017 Mar; 115():180-192. PubMed ID: 27140693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.
    Seeman P; Bzowej NH; Guan HC; Bergeron C; Reynolds GP; Bird ED; Riederer P; Jellinger K; Tourtellotte WW
    Neuropsychopharmacology; 1987 Dec; 1(1):5-15. PubMed ID: 2908095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders.
    Wong EH; Reynolds GP; Bonhaus DW; Hsu S; Eglen RM
    Behav Brain Res; 1996; 73(1-2):249-52. PubMed ID: 8788512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-independent, high-affinity binding of [3H]gamma-aminobutyric acid in human neurological disorders.
    Lloyd KG; Dreksler S; Shemen L; Davidson L
    Adv Exp Med Biol; 1979; 123():399-418. PubMed ID: 160192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The human platelet. A diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders.
    Stahl SM
    Arch Gen Psychiatry; 1977 May; 34(5):509-16. PubMed ID: 140632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D2-like sites in schizophrenia, but not in Alzheimer's, Huntington's, or control brains, for [3H]benzquinoline.
    Seeman P; Guan HC; Nobrega J; Jiwa D; Markstein R; Balk JH; Picetti R; Borrelli E; Van Tol HH
    Synapse; 1997 Feb; 25(2):137-46. PubMed ID: 9021894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GABA and neuropsychiatric disorders.
    Enna SJ
    Can J Neurol Sci; 1980 Aug; 7(3):257-9. PubMed ID: 6449991
    [No Abstract]   [Full Text] [Related]  

  • 14. [Elevation of proinflammatory cytokines level at early age as the risk factor of neurological and mental pathology development].
    Zubarev OE; Klimenko VM
    Ross Fiziol Zh Im I M Sechenova; 2011 Oct; 97(10):1048-59. PubMed ID: 22292271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid signalling in embryonic and adult neurogenesis: possible implications for psychiatric and neurological disorders.
    de Oliveira RW; Oliveira CL; Guimarães FS; Campos AC
    Acta Neuropsychiatr; 2019 Feb; 31(1):1-16. PubMed ID: 29764526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative Stress and the Central Nervous System.
    Salim S
    J Pharmacol Exp Ther; 2017 Jan; 360(1):201-205. PubMed ID: 27754930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin: alterations in the central nervous system in neurological diseases.
    Beal MF; Uhl G; Mazurek MF; Kowall N; Martin JB
    Res Publ Assoc Res Nerv Ment Dis; 1986; 64():215-57. PubMed ID: 2873636
    [No Abstract]   [Full Text] [Related]  

  • 18. D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review.
    Schade S; Paulus W
    Int J Neuropsychopharmacol; 2016 Apr; 19(4):. PubMed ID: 26364274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NCAM in neuropsychiatric and neurodegenerative disorders.
    Brennaman LH; Maness PF
    Adv Exp Med Biol; 2010; 663():299-317. PubMed ID: 20017030
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases.
    Quinones MP; Kaddurah-Daouk R
    Neurobiol Dis; 2009 Aug; 35(2):165-76. PubMed ID: 19303440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.